[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"surgery-complications\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:surgery-complications":139},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,27,0,25,[9,47,70,100,126,148,177,206,228,258,294,327,360,385,411,437,461,486,515,535,563,585,616,639,663],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100644314","the-prevalence-of-hyperglycemia-in-surgical-patients-with-pre-diabetes-100644314",false,"NCT07662980","The Prevalence of Hyperglycemia in Surgical Patients With Pre-diabetes","Inclusion Criteria:\n\n* Hemoglobin A1c measurement between 6 and 6.4%\n* Scheduled for non-cardiac surgery\n\nExclusion Criteria:\n\n* Age\\>18\n* Pregnancy\n* Any formal diabetes diagnosis\n* Current use of medications that influence blood glucose regardless of the indication\n* Undergoing cardiac, intracranial neurosurgery, bariatric, or pancreatic surgeries","ALL","18 Years",{"count":19,"type":20},750,"ESTIMATED","30 Days","OBSERVATIONAL","The goal of this study is to measure the prevalence and risks of hyperglycemia in surgical patients with prediabetes. The main questions it aims to answer are:\n\n* What is the prevalence of hyperglycemia in surgical patients with prediabetes?\n* What is the relative risk of postoperative complications associated with hyperglycemia?\n\nTo answer these questions, surgical patients with prediabetes will undergo universal glucose measurement in the perioperative period. Glucose data will be analyzed in conjunction with electronic health record (EHR) data describing patient outcomes.",[25,26,27,28],"Prediabetes or Diabetes","Surgery Complications","Non-Cardiac\u002F Non-Thoracic Surgery","Stress Hyperglycemia",[30,31,32,33],"Prediabetes","Prevalence","Surgical Complications","Perioperative Hyperglycemia","NOT_YET_RECRUITING","2026-06-17",{"date":37,"type":38},"2026-06-23","ACTUAL",{"date":40,"type":20},"2027-05-01",{"date":42,"type":20},"2028-05-01",{"name":44,"class":45},"University of Calgary","OTHER",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":46},"100641566","the-accelerate-pilot-trial-100641566","NCT07655414","The ACCELERATE Pilot Trial","Advancing Cognition and Cognitive Reserve Before ELective Surgery to Enhance Cognitive Recovery And TrajEctories (ACCELERATE)Trial: a Pilot Multicenter Randomized Trial","Inclusion Criteria:\n\n* Age \\>\u002F= 60 years\n* Planned, inpatient, surgical procedures: abdominal, orthopedic, spine, thoracic, pelvic, ENT, and vascular\n* Clinical Frailty Scale (CFS) score \\>\u002F= 4\n* Expected time to surgery \\>\u002F= 4 weeks\n* Cognitive capacity to independently consent for surgery\n\nExclusion Criteria:\n\n* Cardiac and intracranial neurosurgery procedures\n* Visual impairment\n* Lack of English fluency","60 Years",{"count":56,"type":20},103,"INTERVENTIONAL",[59],"NA","The Advancing Cognition and Cognitive reserve before ELective surgery to Enhance cognitive Recovery And TrajEctories (ACCELERATE) Pilot Trial estimates whether our novel, coach-supported cognitive prehabilitation strategy will achieve adequate intervention adherence in the context of a feasible multicenter trial protocol.",[26],"2026-06-15",{"date":35,"type":38},{"date":65,"type":20},"2026-09",{"date":67,"type":20},"2029-09",{"name":69,"class":45},"Ottawa Hospital Research Institute",{"id":71,"slug":72,"hasResults":12,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":78,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":57,"phases":81,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":46},"100639499","real-time-acute-kidney-injury-perioperative-prediction-clinical-trial-100639499","NCT07604662","Real-Time Acute Kidney Injury Perioperative Prediction Clinical Trial","Prediction of Acute Kidney Injury (AKI) After Surgery: A Pragmatic Three-Arm Cluster-Randomized Trial","ML-AKI","Inclusion Criteria:\n\n* Adults ≥18 years undergoing non-obstetric surgery at UCSF.\n* Inpatient cases with expected overnight stay.\n* Baseline eGFR ≥15 mL\u002Fmin\u002F1.73 m².\n* Managed by an attending anesthesiologist randomized to one of three arms (CRNAs\u002Fresidents follow attending).\n* Data available in the UCSF EHR for risk scoring and outcomes.\n\nExclusion Criteria:\n\n* Obstetric procedures.\n* Chronic dialysis patients.\n* Kidney transplant recipients.\n* Cases without baseline creatinine\u002FeGFR or missing essential EHR elements needed for scoring\u002Foutcomes (operational exclusions).\n* Outpatient procedures without expected overnight stay.",true,{"count":80,"type":20},25518,[59],"This investigator-initiated, pragmatic trial evaluates whether displaying a machine learning (ML)- derived perioperative AKI risk score-alone or paired with an interruptive Best\u002FOur Practice Advisory (BPA\u002FOPA)-improves kidney-protective care and reduces kidney injury after non-obstetric surgery at UCSF. Approximately 75-100 attending anesthesiologists (clusters) are randomized 1:1:1 to: (a) Control (risk score hidden), (b) Score Only (visible preoperative AKI risk probability with passive KDIGO bundle recommendation), or (c) Score + BPA (visible risk plus interruptive KDIGO prompt for high-risk patients). CRNAs\u002Fresidents follow their attending' s assignment. Adult inpatients (age ≥18) with expected overnight stay and eGFR ≥15 mL\u002Fmin\u002F1.73 m² are included; obstetrics, chronic dialysis, and kidney transplant patients are excluded. The underlying preoperative model was prospectively validated at UCSF and outperforms anesthesiologist risk estimation reported in the literature. The model was reviewed and approved by the AI Oversight Committee at UCSF. Primary endpoint is the continuous change in serum creatinine (mg\u002FdL) from baseline to POD 1-2. Secondary outcomes include KDIGO-defined AKI, adherence to bundle elements (hemodynamics, balanced fluids, nephrotoxin avoidance, glycemic control), intraoperative hypotension time, fluid volumes, nephrotoxin exposure, perioperative hyperglycemia, length of stay, unplanned ICU transfer, readmission, dialysis, and in-hospital mortality. Data are obtained from the EHR; analysts are blinded. No direct subject interaction is planned; the investigators will request a waiver of patient consent. The study aims to demonstrate that ML-enabled, workflow-embedded decision support can safely and feasibly improve guideline concordant care and decrease early postoperative kidney injury.",[84,26,85],"Acute Kidney Injury","Anesthesia",[84,87,88,89,90],"Surgical Outcomes","Machine Learning","Clinical Decision Support","Electronic Health Records","2026-05-19",{"date":93,"type":38},"2026-05-22",{"date":95,"type":20},"2026-10-15",{"date":97,"type":20},"2027-12-15",{"name":99,"class":45},"University of California, San Francisco",{"id":101,"slug":102,"hasResults":12,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":46},"100637996","perioperative-predictive-value-of-physical-activity-on-short--and-long-term-morbidity-and-mortality-100637996","NCT07603622","Perioperative Predictive Value of Physical Activity on Short- and Long-term Morbidity and Mortality","PeriopPrePA","Inclusion Criteria:\n\n* Adult patients (equal to or over 18 years) undergoing elective non-cardiac surgery at the two study sites, Karolinska University Hospital Solna and Karolinska University Hospital Huddinge\n\nExclusion Criteria:\n\n* Patients under the age of 18, transplant, day surgery, acute surgery, anesthesia monitoring, brachy therapy and gamma knife interventions. In case of multiple surgeries, only the first will be included.",{"count":108,"type":20},50000,"Over 300 million surgeries are performed globally every year. Complications after surgery - infections, cardiovascular conditions, postoperative pulmonary complications and renal impairment - affect survival and quality of life.\n\nAge and co-morbidity are unmodifiable factors, contributing to increased risk of these perioperative complications. However, a modifiable risk factor is physical activity. This study aims to test if self reported physical activity has added predicted value, beyond established risk factors, for predicting perioperative morbidity and mortality.",[85,111,26],"Surgery",[113,114,115,116],"Perioperative medicine","Outcome","Mortality","Morbidity","RECRUITING","2026-05-18",{"date":93,"type":38},{"date":121,"type":20},"2026-05-01",{"date":123,"type":20},"2026-11-30",{"name":125,"class":45},"Karolinska Institutet",{"id":127,"slug":128,"hasResults":12,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":57,"phases":136,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":46},"100555374","the-strive-before-surgery-trial-100555374","NCT06511258","The STRIVE Before Surgery Trial","The STRIVE Before Surgery Pilot Trial: a Vanguard Pragmatic Multicenter Randomized Trial of Structured TRaining to Improve Fitness in a Virtual Environment (STRIVE) Before Surgery","STRIVE","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Scheduled, or on the pathway, for inpatient abdominal, thoracic, pelvic, head-and-neck or vascular surgery\n3. Expected surgery date between 3 and 12 weeks from enrollment\n4. Valid provincial health insurance number\n5. Access to internet-enabled device\n6. Email address\n\nExclusion Criteria:\n\n1. Inability to read and communicate in English\n2. Cognitive impairment preventing ability to provide informed consent independently\n3. No telephone\u002Fcell phone\n4. Cardiac, neurological or orthopedic procedure\n5. Surgery with no curative intent (palliative surgery)\n6. Patient not interested in participating in the context of their TAPA score\n7. Any of the following cardiovascular conditions:\n\n   1. Severe valvular heart disease that limits a patient's ability to ambulate on level ground, or is associated with syncope or dyspnea\n   2. Severe cardiac dysrhythmias that limit a patient's ability to ambulate on level ground, or is associated with syncope or dyspnea\n   3. Recent myocardial infarction (within 6 weeks prior to enrollment - based on the Heart and Stroke Foundation's HeartWalk program)",{"count":135,"type":20},902,[59],"The STRIVE Before Surgery Trial evaluates patient-reported disability at 90 days after surgery following participating in a home-based multimodal prehabilitation program supported through an online platform. Half of the participants will be randomized into the prehabilitation group, while the other half will be randomized into the control group.",[139,140],"Surgery-Complications","Disability Physical","2026-04-27",{"date":121,"type":38},{"date":144,"type":38},"2024-09-05",{"date":146,"type":20},"2031-12-01",{"name":69,"class":45},{"id":149,"slug":150,"hasResults":12,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":12,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":57,"phases":158,"briefSummary":160,"conditions":161,"keywords":163,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":46},"100590582","phase-3-mitigating-delirium-with-fluvoxamine-treatment-for-non-cardiac-surgery-100590582","NCT06969287","Mitigating Delirium With Fluvoxamine Treatment for Non-Cardiac Surgery","Mitigating Delirium With Fluvoxamine Treatment for Non-Cardiac Surgery (MD FluNCS)","MD FluNCS","Inclusion Criteria:\n\n* English-speaking\n* elective non-cardiac or non-intracranial surgery requiring at least a 2-day hospital length of stay\n\nExclusion Criteria:\n\n* Received investigational drug within the last 7 weeks\n* lack of capacity to provide informed consent\n* prior known intolerance or allergy to SSRIs or fluvoxamine\n* planned postoperative ventilation\n* drug or alcohol dependence\n* preoperative use of non-NSAID medications with drug-drug interactions of Class X (Avoid Combination) or D (Consider Therapy Modification)\n* risk of serotonin syndrome (St John's Wort, SSRIs, or TCA)",{"count":157,"type":20},46,[159],"PHASE3","The investigation will establish biological plausibility and infrastructure required for a multisite clinical trial evaluating the re-purposing of fluvoxamine to mitigate postoperative delirium risk in geriatric patients undergoing non-cardiac non-intracranial surgery.",[162,139],"Delirium",[164,165,166,167],"delirium","geriatric","surgery","fluvoxamine","2026-04-24",{"date":170,"type":38},"2026-04-29",{"date":172,"type":38},"2026-04-06",{"date":174,"type":20},"2028-04-01",{"name":176,"class":45},"Washington University School of Medicine",{"id":178,"slug":179,"hasResults":12,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":185,"targetDuration":187,"studyType":22,"phases":4,"briefSummary":188,"conditions":189,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":205},"100631915","simplified-exercise-based-risk-assessment-in-lung-cancer-100631915","NCT07506889","Simplified Exercise-based Risk Assessment in Lung Cancer","EXercise-based Evaluation of Ventilatory Efficiency for enHanced Risk Assessment in Lungcancer trEatment Using End-tidal CO2: a Multicenter, Prospective Study","EXHALE-CO2","Inclusion Criteria:\n\n* Lung Cancer Diagnosis\n* Age of at least 18 years\n\nExclusion Criteria:\n\n* Not able to perform cycle ergometer exercise\n* Not able to understand spoken or written Swedish",{"count":186,"type":20},500,"1 Year","Physiological evaluation is part of the preoperative risk estimation in patients with lung cancer, and it aids in the choice of treatment. Ventilatory efficiency during exercise has emerged as a strong predictor of major postoperative complications, so far determined during a maximal cardiopulmonary exercise test. However, this test is limited by its availability and high cost, due to the requirement of high-technological equipment and advanced expertise. The current project aims to evaluate a simplified and accessible method for risk evaluation before decision on treatment in lung cancer. It builds on recent advances in technology and knowledge and combines a simple, low-intensity cycling test with measurement of ventilatory efficiency (end-tidal carbon dioxide pressure) with a handheld monitor. In a prospective, multi-center design the investigators will include patients evaluated for suspected lung cancer. The main objective is to establish threshold values for end-tidal carbon dioxide associated with low respectively high risk of major complications in patients undergoing surgery. In addition, the study aims to determine if end-tidal carbon dioxide can predict severe side-effects during neoadjuvant or curatively aiming systemic therapy. The project is closely linked to clinical practice, and the results can be easily implemented due to the simple and cost-efficient methodology. the suggested simplified approach would also allow access to physiological evaluation where more advanced methods are unavailable.",[190,191,26,192,193,194],"Lung Cancer (Diagnosis)","Lobectomy","Neoadjuvant Chemoimmunotherapy","End-Tidal Carbon Dioxide","Exercise","2026-04-02",{"date":197,"type":38},"2026-04-08",{"date":199,"type":20},"2026-04-01",{"date":201,"type":20},"2029-12",{"name":203,"class":204},"Linkoeping University","OTHER_GOV",5,{"id":207,"slug":208,"hasResults":12,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":57,"phases":216,"briefSummary":217,"conditions":218,"keywords":4,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":224,"leadSponsor":226,"locationsCount":46},"100618708","postoperative-complications-of-ankle-arthroscopy-100618708","NCT07335133","Postoperative Complications of Ankle Arthroscopy","Short- and Medium-term Postoperative Complications of Ankle Arthroscopy","ARTHRO2025","Inclusion Criteria:\n\n* Adult patient who has been informed and has signed the consent form\n* Patient scheduled for arthroscopic ankle surgery.\n* Patient affiliated with or covered by a health insurance plan\n\nExclusion Criteria:\n\n* Recent traumatic injury (less than 1 month old), physical therapy assessment impossible\n* Inability to follow up for up to one year\n* Patient under legal protection\n* Pregnant woman, patient under guardianship or conservatorship\n* Patient who has already undergone ankle surgery",{"count":215,"type":20},150,[59],"The goal of this clinical trial is to describe complications that occurred in the year following surgery, based on follow-up surgical consultations and physical therapy sessions.\n\nThe target population is any adult patient who has undergone ankle surgery performed under arthroscopy.\n\nPrimary outcome is description of all complications occurring within one year following ankle arthroscopy. This description will be based on clinical and functional examinations performed by surgeons and physical therapists.\n\nParticipants will be regularly monitored by the surgeon and physical therapist (15 days postoperative, 3 months, 6 months, and 1 year).\n\nThey will complete self-assessment questionnaires and undergo functional physical therapy tests, including ALR RSI, FAAM AVQ, FAAM Sport, CAIT, and Ankle Go.",[219,26],"Ankle Injuries and Disorders","2026-01-05",{"date":222,"type":38},"2026-01-12",{"date":220,"type":38},{"date":225,"type":20},"2028-06",{"name":227,"class":45},"Clinique Saint Jean, France",{"id":229,"slug":230,"hasResults":12,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":234,"eligibilityCriteria":235,"healthyVolunteers":12,"sex":236,"minAge":17,"maxAge":237,"enrollmentInfo":238,"targetDuration":4,"studyType":57,"phases":239,"briefSummary":240,"conditions":241,"keywords":244,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":46},"100529865","one-year-patency-comparison-between-radial-artery-and-no-touch-saphenous-vein-grafts-in-women-undergoing-isolated-cabg-100529865","NCT06179329","One-year Patency Comparison Between Radial Artery and No-touch Saphenous Vein Grafts in Women Undergoing Isolated CABG","No-Touch Saphenous Venous Harvesting TechniQue versUs Radial artEry in Coronary Artery Bypass Grafting in womEN: The QUEEN Multicenter Randomized Controlled Trial","QUEEN","Inclusion Criteria:\n\nWomen aged 18 years or older and younger than 75 years, undergoing isolated and primary myocardial revascularization surgery, with triarterial coronary artery disease (three vessels involved) in vessels subject to surgical revascularization and left ventricular ejection fraction greater than 35%. The target coronary vessels of the study will be those in the territory of the left circumflex artery and the right coronary artery, which must have at least 1.5 mm in diameter, and with proximal obstructive lesions of at least 70%.\n\nExclusion Criteria:\n\n1. Preoperative conditions:\n\n   1. Lack of the patient's written informed consent.\n   2. Presence of poorly controlled diabetes, with a glycated hemoglobin value \\>8 mg\u002Fdl.\n   3. Emergency or salvage surgery, where the intervention needs to be performed quickly due to the critical clinical condition of the patient.\n   4. Renal failure with glomerular filtration rate (creatinine clearance) \\\u003C30 mL\u002Fmin.\n2. Inability to use the saphenous and\u002For radial vein\n\n   1. Positive Allen test using a pulse oximeter\n   2. Presence of abnormal flow detected by means of a Doppler exam in one of the grafts to be used.\n   3. History of vasculitis or Raynaud's syndrome, varicose veins, or history of previous saphenous vein removal\n3. Conditions that may affect patient follow-up\n\n   1. Presence of advanced peripheral arterial disease\n   2. Known contrast allergy: Presence of a documented allergy to the contrast agent used in radiological procedures.\n   3. Impossibility of tracking due to geographic inaccessibility.\n   4. Patients with lack of adherence to guidelines and\u002For prescribed medications.","FEMALE","75 Years",{"count":215,"type":20},[59],"The use of a graft from the left internal thoracic artery to the left anterior descending artery has become the gold standard for the indication of coronary artery bypass grafting. However, choosing a graft for the second-best coronary artery, focusing on long-term patency, is still a challenge. The saphenous vein using the \"no-touch\" technique is an alternative to a radial artery graft, but there is little evidence, especially in women. This randomized clinical study aims to compare the patency of these grafts in the second-best coronary artery in women undergoing coronary artery bypass grafting.",[242,139,243],"Cardiac Disease","Graft Failure",[245,246,247,248],"Cardiovascular Surgery","Coronary Disease","Women","Graft patency","2025-12-04",{"date":251,"type":38},"2025-12-12",{"date":253,"type":38},"2024-01-01",{"date":255,"type":20},"2027-12-30",{"name":257,"class":45},"University of Sao Paulo General Hospital",{"id":259,"slug":260,"hasResults":12,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":12,"sex":16,"minAge":266,"maxAge":267,"enrollmentInfo":268,"targetDuration":4,"studyType":57,"phases":270,"briefSummary":272,"conditions":273,"keywords":280,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":290,"leadSponsor":292,"locationsCount":46},"100609691","phase-2-intravenous-iron-in-kids-with-iron-deficiency-and-scoliosis-study-100609691","NCT07217873","IntraVenous Iron in Kids With Iron Deficiency and Scoliosis Study","IntraVenous Iron in Kids With Iron Deficiency and Scoliosis","IV-KIDS","Inclusion Criteria:\n\n* 10 -19 years old\n* diagnosis of scoliosis or kyphosis\n* scheduled for imminent spinal fusion procedure (\\\u003C6 weeks) at MS-CHONY\n* Iron deficiency or hypoferritinemia, defined as serum ferritin less than or equal to 50 μg\u002FL\n\nExclusion Criteria:\n\n* C-reactive protein \\> 10 mg\u002FL\n* receiving nutritional support by report in the medical chart\n* self-reported history of hypersensitivity reaction to iron-containing supplements\n* self-reported history of receiving intravenous iron supplements\n* self-reported history of iron overloaded state such as hereditary hemochromatosis or hemosiderosis\n* objection to receiving red blood cell transfusions\n* current pregnancy (identified by self-report or documentation of preoperative screening test in the medical record)\n* prisoners\n* patient or parent decides against study participation","10 Years","19 Years",{"count":269,"type":20},120,[271,159],"PHASE2","Adolescents and young adults undergoing spinal fusion surgery for the correction of scoliosis and other spinal deformity are at high risk of perioperative iron deficiency and anemia, yet the means and evidence for optimizing iron status have not been described in this setting. The proposed study is a randomized controlled trial of preoperative intravenous iron supplementation, to identify whether iron deficiency is a modifiable risk factor for adverse surgical outcomes such as red blood cell transfusion and diminished postoperative cognitive and physical capacity in this vulnerable population. Building evidence for patient blood management interventions such as iron supplementation is vital to ensuring high quality care of surgical patients and may reduce unnecessary transfusions amid recent blood shortages.",[274,275,276,26,277,278,279],"Scoliosis Correction","Iron Deficiency","Transfusion Blood","Spinal Fusion","Scoliosis Idiopathic Adolescent","Scoliosis Neuromuscular",[281,282,283,284,285],"scoliosis","iron deficiency","blood transfusion","spinal fusion","iron supplementation","2025-11-21",{"date":288,"type":38},"2025-11-26",{"date":286,"type":38},{"date":291,"type":20},"2027-10-31",{"name":293,"class":45},"Columbia University",{"id":295,"slug":296,"hasResults":12,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":301,"enrollmentInfo":302,"targetDuration":4,"studyType":57,"phases":304,"briefSummary":305,"conditions":306,"keywords":309,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":46},"100563773","phase-2-prevent-cardiac-surgery-associated-aki-trial-100563773","NCT06620523","Prevent Cardiac Surgery Associated AKI Trial","Efficacy of Mitochondrial Directed Therapy in Prevention of Cardiac Surgery Associated AKI Prevent Cardiac Surgery Associated AKI Trial (Prevent CSA-AKI Trial)","Inclusion Criteria:\n\n* Adult 18-70 years of age\n* Undergoing elective CPB (Cardiopulmonary Bypass) surgery\n* Baseline GFR (Glomerular Filtration Rate) ≥45 ml\u002Fmin\n\nExclusion Criteria:\n\n* GFR (Glomerular Filtration Rate) \\\u003C45 ml\u002Fmin\n* Solitary kidney\n* Status post-kidney transplant\n* Pregnant women\n* Allergy to CoQ10\n* Allergy to Glutathione\n* Allergy to Cellulose","70 Years",{"count":303,"type":20},242,[271],"Prevent CSA-AKI (Cardiac Surgery Associated Acute Kidney Injury) trial is a double blinded randomized controlled trial, 242 patients undergoing elective cardiopulmonary bypass surgery (CPB)will either receive a placebo or daily 1200 mg of Co enzyme Q10 (CoQ10) and 1000 mg of Glutathione (GSH), the first dose will be given the day before surgery and continues while admitted up to 1 week. Blood and urine samples will be collected. Adverse events related to the study drugs will be collected.",[307,308,111,139],"Renal Failure","Coronary Artery Disease",[310,311,312,313,314,315,316,317],"cardiac surgery","critical care medicine","anesthesiology","nephrology","cardiopulmonary bypass","renal failure","aki","supplement","2025-10-03",{"date":320,"type":38},"2025-10-08",{"date":322,"type":38},"2024-07-18",{"date":324,"type":20},"2028-06-17",{"name":326,"class":45},"George Washington University",{"id":328,"slug":329,"hasResults":12,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":333,"eligibilityCriteria":334,"healthyVolunteers":12,"sex":16,"minAge":335,"maxAge":4,"enrollmentInfo":336,"targetDuration":4,"studyType":57,"phases":338,"briefSummary":339,"conditions":340,"keywords":344,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":359},"100536688","depth-of-anesthesia-on-postoperative-delirium-and-cognitive-after-surgery-100536688","NCT06268080","Depth of Anesthesia on Postoperative Delirium and Cognitive After Surgery","Preserving Brain Health After Surgery: Does Light General Anesthesia Reduce Postoperative Delirium and Cognitive Decline Compared With Deep General Anesthesia in Older Adults?","Balanced-2","Inclusion Criteria:\n\n* Patients aged ≥ 65 years, and Māori, Pacific or Indigenous participants aged ≥ 55 years who are undergoing major elective or non-elective surgery with expected surgical duration ≥ 2 hours and postoperative hospital stay ≥ 2 nights.\n* Having general anesthesia using total intravenous anesthesia (TIVA) with pEEG monitoring\n* Able to provide informed consent (including patients with mild preoperative neurocognitive disorders)\n\nExclusion Criteria:\n\n* Intracranial or cardiac surgery\n* Undergoing surgery with 'wake up' test\n* Previous enrollment in Balanced-2 study\n* Terminal illness with expected survival \\\u003C3 months\n* Emergency surgery within 6 hours of presentation to hospital\n* Cognitive impairment with no capacity to consent or activated enduring power of attorney\n* Clinically impaired and unable to consent due to acute pathology or preoperative delirium","55 Years",{"count":337,"type":20},2766,[59],"The goal of this clinical trial (Balanced-2 study) is to compare light to deep general anesthesia using widely available brain monitors, to see if 'light' anesthesia could reduce rates of delirium, cognitive decline, and disability in older adults undergoing major surgery.\n\nDelirium is the most common serious surgical complication, occurring in an estimated one in four older adults undergoing major surgery. Delirium causes significant distress to patients and family, and is associated with prolonged hospital stay, physical disability, progression to dementia-like illnesses, and discharge to long-term care. Between 10 - 30% of adults aged 70 years and above have surgery every year, and preserving brain health and wellbeing is an important priority during this time.\n\nOlder adults (aged ≥65 years, or Indigenous, Pacific patients aged ≥55 years) undergoing major surgery with general anesthesia (excluding heart and brain surgery) and able to provide consent will be able to participate. Participants will be randomized to two groups - a lighter general anesthesia group and a deeper general anesthesia group using processed electroencephalography (a brain monitor that provides information on depth of anesthesia using brain waves). The anesthesiologist will titrate anesthetic drugs according to the brain monitor. Participants will be followed up to determine if they experience delirium after surgery, and longer term impact of delirium such as cognitive and physical decline will also be measured.\n\nIf found to be effect, this simple, cheap, and widely available treatment could reduce disability, preserve brain health and wellbeing of many older adults undergoing surgery worldwide, and save millions in healthcare dollars.",[341,85,139,342,162,343],"Delirium, Postoperative","Cognition Disorder","Cognitive Decline",[345,346,347,348,349],"randomized controlled trial","multicentre","clinical trial","depth of anaesthesia","postoperative delirium","2025-09-22",{"date":352,"type":38},"2025-09-25",{"date":354,"type":38},"2024-05-20",{"date":356,"type":20},"2028-12-31",{"name":358,"class":204},"Auckland City Hospital",3,{"id":361,"slug":362,"hasResults":12,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":366,"eligibilityCriteria":367,"healthyVolunteers":12,"sex":16,"minAge":368,"maxAge":4,"enrollmentInfo":369,"targetDuration":4,"studyType":57,"phases":371,"briefSummary":373,"conditions":374,"keywords":4,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":384},"100495253","phase-4-remimazolam-vs-propofol-total-intravenous-anesthesia-on-outcomes-after-major-noncardiac-surgery-100495253","NCT05728775","REmimazolam vs Propofol Total Intravenous Anesthesia on Outcomes After Major Noncardiac SurgEry","REmimazolam vs Propofol Total Intravenous Anesthesia on Outcomes After Major Noncardiac SurgEry (REPOSE-2): A Multicenter Randomized Controlled Trial","REPOSE-2","Inclusion Criteria:\n\n* Age ≥45 years;\n* Undergoing elective major surgery under general anesthesia (expected surgery time \\>2 h, expected length of postoperative stay \\>2 d);\n* Fulfilling ≥1 of the following criteria:\n\n  1. history of coronary artery disease;\n  2. history of stroke;\n  3. history of congestive heart failure;\n  4. preoperative NT-proBNP \\>200 pg\u002FmL or BNP\\>92 pg\u002FmL;\n  5. age ≥70 years;\n  6. diabetes requiring medical treatment;\n  7. ASA status 3 or 4;\n  8. history of chronic kidney disease (preoperative sCr \\>133 μmol\u002FL or 1.5 mg\u002FdL);\n  9. history of peripheral arterial disease;\n  10. preoperative serum albumin \\\u003C30 g\u002FL;\n  11. preoperative hemoglobin \\\u003C100 g\u002FL.\n\nExclusion Criteria:\n\n* Undergoing organ transplantation, cardiac, craniocerebral, burn or interventional operations;\n* Low risk or minor surgery\n* End-stage renal disease requiring renal-replacement therapy;\n* Hepatic dysfunction (Child B or C);\n* Previous liver or kidney transplantation;\n* Previous allergy to general anesthetics;\n* Unable to receive bispectral index monitoring;\n* ASA score ≥5;\n* Exposure to general anesthesia in prior 30 days or anticipated re-exposure to general anesthesia within 30 days after surgery;\n* Need for prolonged airway protection or mechanical ventilatory support after surgery;\n* Current participation in another interventional study;\n* Previous participation in this study;\n* Pregnant or breastfeeding women.","45 Years",{"count":370,"type":20},7188,[372],"PHASE4","The goal of this randomized controlled trial is to compare total intravenous anesthesia with remimazolam vs total intravenous anesthesia with propofol in moderate-to-high risk patients undergoing major elective noncardiac surgery under general anesthesia. The primary hypothesis is that total intravenous anesthesia with remimazolam can increase days alive and out of hospital at postoperative day 30 compared with total intravenous anesthesia with propofol.",[85,139],"2025-08-19",{"date":377,"type":38},"2025-08-26",{"date":379,"type":38},"2023-04-03",{"date":381,"type":20},"2027-12-31",{"name":383,"class":45},"Nanfang Hospital, Southern Medical University",44,{"id":386,"slug":387,"hasResults":12,"nctId":388,"briefTitle":389,"officialTitle":389,"acronym":390,"eligibilityCriteria":391,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":392,"targetDuration":4,"studyType":57,"phases":394,"briefSummary":395,"conditions":396,"keywords":4,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":410},"100515434","trajectories-of-recovery-after-intravenous-propofol-versus-inhaled-volatile-anesthesia-trial-100515434","NCT05991453","Trajectories of Recovery After Intravenous Propofol Versus Inhaled VolatilE Anesthesia Trial","THRIVE","Inclusion Criteria\n\nEach patient must meet all of the following criteria:\n\n1. Aged 18 years or older\n2. Undergoing elective non-cardiac surgery expected to last ≥ 60 min requiring general anesthesia with a tracheal tube or laryngeal mask airway (or similar supra-glottic device)\n\nExclusion Criteria\n\nPatients will not be enrolled if any of the following criteria are met:\n\n1. Inability to provide informed consent in English (at all study sites) or Spanish (at sites where Spanish consent is provided as an option)\n2. Pregnancy (based on patient report or positive test on the day of surgery)\n3. Surgical procedure requiring general, regional, neuraxial anesthesia administered by an anesthesia clinician (anesthesiologist, CRNA, anesthesiology assistant) occurring within 30 days prior to or planned to occur within 30 days after surgery date\n4. Contraindication to propofol TIVA or INVA (for example, documented allergy to propofol, history of severe postoperative nausea or vomiting, concern for or history of malignant hyperthermia) based on self-report\n5. Surgical procedures requiring a specific general anesthesia technique (for example, TIVA required for neuromonitoring).\n6. Locally approved, written protocol mandating a particular anesthetic technique\n7. History of possible or definite intraoperative awareness during general anesthesia based on patient self-report\n8. Planned postoperative intubation\n9. Current incarceration",{"count":393,"type":20},13000,[59],"The investigators will conduct a 13,000-patient randomized multi-center trial to determine (i) which general anesthesia technique yields superior patient recovery experiences in any of three surgical categories ((a) major inpatient surgery, (b) minor inpatient surgery, (c) outpatient surgery) and (ii) whether TIVA confers no more than a small (0.2 %) increased risk of intraoperative awareness than INVA in patients undergoing both outpatient and inpatient surgeries",[139,397,398,85,111,399,400,401],"Anesthesia Complication","Anesthesia Awareness","Quality of Life","Pain, Postoperative","Anesthesia Morbidity","2025-07-30",{"date":404,"type":38},"2025-08-05",{"date":406,"type":38},"2023-09-13",{"date":408,"type":20},"2028-07-31",{"name":176,"class":45},20,{"id":412,"slug":413,"hasResults":12,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":417,"eligibilityCriteria":418,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":419,"targetDuration":4,"studyType":57,"phases":421,"briefSummary":422,"conditions":423,"keywords":424,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":4},"100600784","effects-of-gdht-goal-directed-hemodynamic-therapy-using-a-non-invasive-hemodynamic-monitoring-in-elective-neurosurgery-100600784","NCT07101991","Effects of GDHT (Goal Directed Hemodynamic Therapy) Using a Non-invasive Hemodynamic Monitoring in Elective Neurosurgery","Effects of Goal-directed Fluid Management Guided by a Non-invasive Device on the Incidence of Postoperative Complications in Neurosurgery: a Multicenter, Prospective, Randomized, Controlled Study","NCHGDT","Inclusion Criteria:\n\nSubjects will be eligible for the trial if they meet all of the following criteria:\n\n* Age ≥ 18 years\n* Elective brain surgery with an expected duration ≥ 2 h\n* Category 1-3 according to the ASA (American Society of Anesthesiologists) Physical Status Classification\n* Lateral or supine operative position\n* Signed the relevant informed consent form\n\nExclusion Criteria:\n\nSubjects will not be eligible for the trial if they meet any of the following criteria:\n\n* Category 4 according to the ASA Physical Status Classification\n* Surgery for traumatic brain injury or acute hemorrhagic stroke\n* Awake brain surgery\n* Osmotherapy before surgery (with the exception of prophylactic administration of osmotic agents according to institutional standards)\n* Unavailability of hemodynamic monitoring data\n* Cardiac arrhythmia with irregular cardiac rhythm\n* Known hypersensitivity to the active substance or to any of the excipients of IMP (Investigational Medicinal Product)\n* Pregnancy and lactation",{"count":420,"type":20},140,[59],"This study aims to assess the safety and efficacy of GDHT using the non-invasive Starling™ SV System in elective neurosurgery. The tested group of patients (n=70) will be compared with a control group (n=70), where hemodynamic management will be guided by standard vital signs monitoring.",[26],[425,426,427],"neurosurgery","goal-directed therapy","adverse events","2025-07-28",{"date":430,"type":38},"2025-08-03",{"date":432,"type":20},"2025-09",{"date":434,"type":20},"2028-11",{"name":436,"class":45},"Brno University Hospital",{"id":438,"slug":439,"hasResults":12,"nctId":440,"briefTitle":441,"officialTitle":441,"acronym":4,"eligibilityCriteria":442,"healthyVolunteers":78,"sex":16,"minAge":17,"maxAge":443,"enrollmentInfo":444,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":446,"conditions":447,"keywords":449,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":454,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":459,"locationsCount":46},"100594650","incidence-of-hypotension-in-the-post-anesthesia-care-unit-pacu-100594650","NCT07022210","Incidence of Hypotension in the Post-anesthesia Care Unit (PACU).","Inclusion Criteria:\n\n* patients over 18 years old\n* patients undergoing a procedure under general anesthesia\n* patients who have consented to data processing\n* postoperative stay in PACU\n\nExclusion Criteria:\n\n* patients younger than 18 years old.\n* patients transferred directly to the ICU\u002FAnesthesiology and Resuscitation Department after surgery without staying in the recovery room.\n* patients with incomplete medical documentation or missing blood pressure values in the recovery room.\n* patients with a pre-existing diagnosis of resistant hypotension or unstable hemodynamics before surgery\n* patients with a history of long-term use of anxiolytics, antipsychotics, or other psychotropic medications that may affect cognitive function, emotional state, or predictive outcomes\n* patient refusal to participate in the study (including cases where they initially consented), with an emphasis on respecting patient autonomy","105 Years",{"count":445,"type":20},100,"The perioperative period poses a heightened risk of complications for patients, including hypotension. While the issue of intraoperative hypotension is well-documented in medical literature, the occurrence and causes of hypotension in the post-anesthesia care unit often receive less attention. This phase of postoperative care, however, is vital for ensuring patient stability and preventing severe consequences. Failure to identify and manage a drop in blood pressure can lead to hypoperfusion of critical organs, increasing the risk of morbidity and mortality. The aim of this study is to examine the frequency of hypotension in the post-anesthesia care unit-defined as systolic blood pressure \\\u003C90 mmHg or a drop of more than 20% from baseline-and to identify factors contributing to its development.",[448,139],"Hypotension During Surgery",[450,451,166,452],"hypotension","post-anesthesia care unit","adult","2025-07-06",{"date":455,"type":38},"2025-07-10",{"date":457,"type":38},"2025-06-15",{"date":121,"type":20},{"name":460,"class":45},"Tomas Bata Hospital, Czech Republic",{"id":462,"slug":463,"hasResults":12,"nctId":464,"briefTitle":465,"officialTitle":465,"acronym":4,"eligibilityCriteria":466,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":467,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":469,"conditions":470,"keywords":472,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":478,"startDateStruct":480,"completionDateStruct":482,"leadSponsor":484,"locationsCount":46},"100596287","comparison-of-endoscopy-and-esophagram-for-the-routine-evaluation-of-anastomosis-after-mckeown-esophagectomy-100596287","NCT07043491","Comparison of Endoscopy and Esophagram for the Routine Evaluation of Anastomosis After McKeown Esophagectomy","Inclusion Criteria:\n\nThe inclusion criteria required patients to have routinely undergone either endoscopy or an esophagram for the postoperative evaluation of anastomosis.\n\nExclusion Criteria:\n\nWe excluded the patient with histologically confirmed benign tumors of the esophagus or esophagogastric junction and the patient who had incomplete data.",{"count":468,"type":20},2,"This retrospective cohort study reviewed patients who underwent McKeown esophagectomy. All patients routinely underwent either endoscopy or esophagram for the evaluation of anastomosis on postoperative day 7. The initiation of oral intake depended on the status of anastomosis according to the assessment result of endoscopy or esophagram. All patients were followed up for six months after the assessment of anastomosis.",[471,139],"Esophageal Cancer",[473,474,475,476],"Esophageal cancer","Endoscopy","Esophagram","McKeown esophagectomy","2025-06-21",{"date":479,"type":38},"2025-06-29",{"date":481,"type":38},"2024-11-04",{"date":483,"type":20},"2025-12-01",{"name":485,"class":45},"Sun Yat-sen University",{"id":487,"slug":488,"hasResults":12,"nctId":489,"briefTitle":490,"officialTitle":491,"acronym":4,"eligibilityCriteria":492,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":493,"targetDuration":187,"studyType":22,"phases":4,"briefSummary":494,"conditions":495,"keywords":502,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":506,"lastUpdatePostDateStruct":507,"startDateStruct":509,"completionDateStruct":511,"leadSponsor":513,"locationsCount":46},"100479104","compliance-with-eras-protocol-in-pancreatic-surgery-stress-response-and-outcomes-100479104","NCT05518643","Compliance With ERAS Protocol in Pancreatic Surgery, Stress Response and Outcomes","Enhanced Recovery Program, Patient Reported Outcomes, Surgery-specific Outcomes and Stress Response After Pancreatic Surgery: A Prospective Observational Cohort Study by the Thessalic Pancreas Study Group (ThePANas).","Inclusion Criteria:\n\n* all pancreatic surgery patients\n* above the age of 18\n* fluent greek speakers\n* without communication barriers\n\nExclusion Criteria:\n\n* younger than 18 years-old\n* unable or unwilling to participate\n* other surgical procedures\n* communication barriers\n* lost to follow-up",{"count":269,"type":20},"The purpose of this study is to evaluate the impact of compliance with enhanced recovery after surgery (ERAS) program on patient reported outcomes (PROs), surgery-specific outcomes and stress response after pancreatic surgery.\n\nThis prospective observational study will include all consecutive patients undergoing pancreatic surgery over a period of three years (2022 - 2025) at two sites, namely University General Hospital of Larissa and IASO Thessalias, in Greece. Patients will be prospectively enrolled after written informed consent. Data will be collected on patient characteristics, surgical and anaesthetic techniques, complications, and length of stay. Quality of life questionnaires will be administered to patients preoperatively, on the fith postoperative day, first follow-up after discharge, one month and six months after the operation. The stress response will be assessed by measuring the Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio (NLR and PLR) preoperatively, and on the first five postoperative days. Data will be collected on pancreatic surgery-specific complications such as delayed gastric emptying (DGE), post-pancreatectomy haemorrhage (PPH) and postoperative pancreatic fistula (POPF) formation. Anonymised data will be uploaded by the principal investigator on a protected excel spreadsheet for analysis.",[496,497,498,499,139,500,501],"ERAS","Pancreas Cancer","Pancreas; Fistula","Delayed Gastric Emptying","Pancreatic Hemorrhage","PROMs",[496,497,501,503,139,504,505,399],"Stress response to surgery","PLR","NLR","2025-04-16",{"date":508,"type":38},"2025-04-22",{"date":510,"type":38},"2022-07-15",{"date":512,"type":20},"2025-06",{"name":514,"class":45},"University of Thessaly",{"id":516,"slug":517,"hasResults":12,"nctId":518,"briefTitle":519,"officialTitle":519,"acronym":520,"eligibilityCriteria":521,"healthyVolunteers":78,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":522,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":524,"conditions":525,"keywords":4,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":527,"lastUpdatePostDateStruct":528,"startDateStruct":530,"completionDateStruct":532,"leadSponsor":533,"locationsCount":468},"100524268","vital-sign-monitor-device-validation---ward-100524268","NCT06106516","Vital Sign Monitor Device Validation - WARD","ViVa-WARD","No inclusion or exclusion criteria",{"count":523,"type":20},1000,"Aim: to assess the validity of CE\u002FFDA approved vital sign monitor devices for clinical use in clinical setting.\n\nPatients: up to 1000 medical and\u002For surgical patients will be included Intervention: Studies with various wirless or novel vital sign monitor devices control: Golden standard measurements or clinical standard devices Outcome: Agreement assessed by bias and limits of agreement between Intervention and control device.",[139,526],"Medical Complication","2025-04-02",{"date":529,"type":38},"2025-04-06",{"date":531,"type":38},"2023-10-24",{"date":356,"type":20},{"name":534,"class":45},"Rigshospitalet, Denmark",{"id":536,"slug":537,"hasResults":12,"nctId":538,"briefTitle":539,"officialTitle":540,"acronym":541,"eligibilityCriteria":542,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":543,"targetDuration":4,"studyType":57,"phases":544,"briefSummary":545,"conditions":546,"keywords":550,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":557,"completionDateStruct":558,"leadSponsor":560,"locationsCount":562},"100515793","study-on-optimal-temperature-during-cardiopulmonary-bypass-thermic-4-100515793","NCT05996120","Study on Optimal Temperature During Cardiopulmonary Bypass (THERMIC-4)","Normothermic Versus Hypothermic Cardiopulmonary Bypass in Adult Cardiac Surgery: a Multicentre Feasibility Randomised Controlled Trial","THERMIC-4","INCLUSION CRITERIA\n\nParticipants may enter the trial if all of the following apply\n\n1. Adult patients (≥ 18 years) scheduled for coronary artery bypass surgery and\u002For valve replacement\u002F repair, either in the elective or urgent setting.\n2. European System for Cardiac Operative Risk Evaluation (EuroSCORE) II of 2 or higher.\n3. Able to understand and communicate to provide informed consent.\n4. Able to read and understand the English language.\n\nEXCLUSION CRITERIA\n\nParticipants may not enter the trial if any of the following apply:\n\n1. Patients undergoing coronary artery bypass surgery in combination with other procedures including cardiac or vascular procedures that require deep hypothermic arrest.\n2. Patients undergoing emergency or salvage surgery.\n3. Patients undergoing off-pump cardiac surgery.\n4. Patients who are participating in another interventional trial.\n5. Unable to provide informed consent.",{"count":445,"type":20},[59],"In order to perform heart surgery, a machine called cardiopulmonary bypass (CPB), or more commonly known as a heart-lung machine, is used to maintain the circulation of oxygenated blood needed by the rest of the body and its organs.\n\nHistorically, when a patient is connected to CPB, their body is cooled below the normal body temperature. This is known as hypothermia. This is because scientific studies have previously shown that reduced body temperature lowers metabolism and therefore offers more protection to the brain and other organs due to the reduced oxygen requirement. The evidence supporting this practice, however, has been challenged throughout the history of cardiac surgery, with studies supporting that normothermia, or normal body temperature, is a safe alternative. Despite this, the practice of hypothermia has persisted. Published data from a survey of 139 cardiac surgeons in the United Kingdom showed that 84% still routinely employ hypothermic CPB during surgery.\n\nTo assess whether normothermic or hypothermic CPB is safer, a clinical trial requiring a large sample size and high recruitment rates will be required. Therefore, the investigators aim to assess firstly the feasibility of trial recruitment and allocation adherence in this study. 100 adults across 10 different cardiac surgery centres in the United Kingdom will be recruited to a multicentre feasibility randomised controlled trial comparing normothermia (active comparator) against hypothermia (control comparator) during cardiopulmonary bypass in cardiac surgery. This study will also test the ability of the Cardiothoracic Interdisciplinary Research Network (CIRN), a trainee-led research collaborative, to collect pilot data on Major Adverse Cardiac and Cerebrovascular Events (MACCE) using a regulation-approved electronic application HealthBitⓇ. Participants will also be asked to complete quality of life surveys. The results of this study will subsequently inform a large, adequately powered randomised controlled trial for optimal temperature management during CPB.",[547,548,549,139],"Ischemic Heart Disease","Valvular Heart Disease","Cardiovascular Diseases",[314,551,552,553],"hypothermia","myocardial protection","neurologic protection","2025-03-31",{"date":556,"type":38},"2025-04-03",{"date":354,"type":38},{"date":559,"type":20},"2026-02",{"name":561,"class":45},"University of Leicester",11,{"id":564,"slug":565,"hasResults":12,"nctId":566,"briefTitle":567,"officialTitle":568,"acronym":569,"eligibilityCriteria":570,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":571,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":573,"conditions":574,"keywords":4,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":583,"locationsCount":46},"100574811","assessing-pancreatic-fistula-rates-after-distal-pancreatectomy-using-aeon-endostapler-100574811","NCT06764134","Assessing Pancreatic Fistula Rates After Distal Pancreatectomy Using AEON Endostapler","Study Protocol for an Investigator Initiated, Observational Prospective Study, Evaluating the Rate of Postoperative Pancreatic Fistula in Distal Pancreatectomy Using AEON™ Endostapler","AEON-DP","Inclusion Criteria:\n\n* Age 18 years or older.\n* Ability to understand the nature and consequences of the study.\n* Provision of written informed consent.\n* Scheduled for minimally invasive or open distal pancreatectomy (DP) for any indication, with or without splenectomy and\u002For left adrenalectomy.\n\nExclusion Criteria:\n\n* Inability to comply with study procedures or follow-up.\n* Multivisceral resection beyond left adrenalectomy.\n* History of previous pancreatic surgeries.\n* Expected lack of compliance with the study protocol.\n* Participation in another trial that may interfere with the intervention or outcomes of this study.",{"count":572,"type":20},110,"This prospective, observational study evaluates the rate of postoperative pancreatic fistula (POPF) following distal pancreatectomy (DP) using the AEON™ Endostapler. The study involves 110 patients undergoing DP and assesses primary outcomes based on the International Study Group of Pancreatic Fistula (ISGPF) classification, alongside secondary perioperative parameters. The findings aim to optimize surgical techniques, reduce complications, and improve healthcare outcomes.",[498,497,575,139,111],"Pancreatic Disease","2025-01-02",{"date":578,"type":38},"2025-01-08",{"date":580,"type":38},"2024-11-01",{"date":582,"type":20},"2025-10-31",{"name":584,"class":45},"University Hospital Heidelberg",{"id":586,"slug":587,"hasResults":12,"nctId":588,"briefTitle":589,"officialTitle":590,"acronym":591,"eligibilityCriteria":592,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":593,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":594,"conditions":595,"keywords":597,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":607,"lastUpdatePostDateStruct":608,"startDateStruct":610,"completionDateStruct":612,"leadSponsor":614,"locationsCount":46},"100552325","precision-medicine-in-cardiovascular-surgery-associated-acute-kidney-injury-100552325","NCT06471621","Precision Medicine in Cardiovascular Surgery Associated Acute Kidney Injury","PrEcision Medicine in the Management of Cardiovascular Surgery Associated AKI - PEAK: a Prospective Observational Cohort Study","PEAK","Inclusion Criteria:\n\n* Patients undergoing elective cardiovascular surgery, such as valvular replacement surgery, with or without combined coronary artery bypass graft (CABG), or thoracic or abdominal aortic surgery.\n* Written informed consent obtained prior to surgery.\n\nExclusion Criteria:\n\n* Patients with a kidney transplant or on renal replacement therapy\n* Severe liver failure, defined by the presence of encephalopathy, Factor V \\\u003C 50% and INR \\>1.5 on preoperative blood sample (within 4 weeks).",{"count":445,"type":20},"The goal of this prospective observational study is to define a risk profile for cardiovascular surgery associated acute kidney injury (AKI), using clinical patient characteristics, operation parameters as well as blood and urine laboratory values.\n\nThe main question it aims to answer is:\n\n• Does a combination of the factors mentioned above better predict patient outcome than classical factors used to date in clinical practice?\n\nParticipants of this study are adults aged 18 and above who are scheduled for elective heart or main artery surgery, and who have given written informed consent.",[84,139,596],"Frailty",[598,599,600,601,602,603,604,605,314,606],"Kidney","Renal","Cardiac","Thoracic","Abdominal","Valvular replacement","CABG","Aneurysm","Ischemia","2024-07-17",{"date":609,"type":38},"2024-07-19",{"date":611,"type":38},"2024-06-16",{"date":613,"type":20},"2026-10-31",{"name":615,"class":45},"Insel Gruppe AG, University Hospital Bern",{"id":617,"slug":618,"hasResults":12,"nctId":619,"briefTitle":620,"officialTitle":620,"acronym":621,"eligibilityCriteria":622,"healthyVolunteers":12,"sex":16,"minAge":623,"maxAge":4,"enrollmentInfo":624,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":626,"conditions":627,"keywords":629,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":632,"lastUpdatePostDateStruct":633,"startDateStruct":635,"completionDateStruct":636,"leadSponsor":637,"locationsCount":46},"100547776","functional-assessment-for-surgery-by-a-timed-walk-100547776","NCT06412367","FUNCTIONAL ASSESSMENT FOR SURGERY BY A TIMED WALK","FAST Walk","Inclusion Criteria:\n\n1. Age ≥40 years\n2. ≥1 risk factors for postoperative complications\n3. Elective non-cardiac surgery with expected post-surgery stay ≥2 days\n4. Preoperative 6MWT is feasible\n5. Working knowledge of official language(s) in country of study recruitment\n\nExclusion Criteria:\n\n1. Endovascular surgery\n2. Lower limb orthopedic surgery\n3. Contraindications to 6MWT","40 Years",{"count":625,"type":20},1672,"The FAST Walk study aims to determine whether a walking test called the 6-minute walk test (6MWT) can help identify people who are more likely to experience complications after surgery. This test will be completed before surgery. We hope that the results of this study will help improve care for patients having major surgery in the future.",[139,628],"Postoperative Complications",[630,631],"Six Minute Walk Test","Functional assessment","2024-06-10",{"date":634,"type":38},"2024-06-11",{"date":632,"type":38},{"date":67,"type":20},{"name":638,"class":45},"Unity Health Toronto",{"id":640,"slug":641,"hasResults":12,"nctId":642,"briefTitle":643,"officialTitle":644,"acronym":4,"eligibilityCriteria":645,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":646,"targetDuration":4,"studyType":57,"phases":647,"briefSummary":648,"conditions":649,"keywords":651,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":654,"lastUpdatePostDateStruct":655,"startDateStruct":657,"completionDateStruct":659,"leadSponsor":661,"locationsCount":46},"100547150","use-of-cpetarm-for-risk-stratification-of-patients-with-clti-100547150","NCT06404229","Use of CPETarm for Risk Stratification of Patients With CLTI","Novel Use of Bedside Arm Ergometry CardioPulmonary Exercise Tests for the Risk Stratification of Patients With Chronic Limb-threatening Ischaemia: A Feasibility Trial","Inclusion Criteria:\n\n* Ability and willingness to give written informed consent\n* Diagnosis of chronic limb threatening ischaemia, undergoing one of the following procedures: Infra inguinal bypass, Extra anatomical bypass, Common femoral endarterectomy, Endovascular treatment, Primary amputation\n\nExclusion Criteria:\n\n* Patients with active medical conditions deemed an absolute contraindication for undertaking CPET\n* Ongoing evaluation for coronary artery disease (e.g awaiting stress test or cardiac catheterisation or requiring the up titration of anti anginal medications)\n* Active arrthymic requiring the initiation or up titration of an anti arrthymic medication\n* Active congestive cardiac failure requiring the initiation or up titration of diuretic therapy.\n* Severe cardiac valvular stenosis\n* Physical disability precluding ability to perform CPETarm\n* Psychiatric disorder or dementia precluding them from consenting for research and\u002For undertaking testing and\u002For follow up",{"count":269,"type":20},[59],"This is a prospective cohort study of patients undergoing surgery for chronic limb threatening ischaemia. Prior to surgery, patients will undergo CardioPulmonary Exercise testing (CPET) using an arm ergometer. Feasibility outcome measures will be recorded at testing and participants will be followed up for a period of up to 5 years to obtain clinical outcome measures.",[650,139],"Chronic Limb-Threatening Ischemia",[652,653],"CardioPulmonary Exercise Testing","Risk Stratification","2024-05-03",{"date":656,"type":38},"2024-05-08",{"date":658,"type":20},"2024-05-28",{"date":660,"type":20},"2030-04-28",{"name":662,"class":45},"University of Manchester",{"id":664,"slug":665,"hasResults":12,"nctId":666,"briefTitle":667,"officialTitle":667,"acronym":668,"eligibilityCriteria":669,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":670,"targetDuration":4,"studyType":57,"phases":672,"briefSummary":673,"conditions":674,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":678,"lastUpdatePostDateStruct":679,"startDateStruct":681,"completionDateStruct":683,"leadSponsor":685,"locationsCount":46},"100527871","phase-3-prolonged-hypercoagulability-following-major-liver-resection-for-malignancy-100527871","NCT06153394","Prolonged Hypercoagulability Following Major Liver Resection for Malignancy","PRIORITY","Inclusion Criteria:\n\n1. Adults aged 18 years or older at the time of enrollment.\n2. Requiring major liver resection (\\>2 liver sections) for any oncologic indication.\n3. Requiring postoperative thromboprophylaxis will be included.\n4. Willing and able to perform subcutaneous injections according to the study protocol, or receive injections form a caregiver delegated by the participant.\n\nExclusion Criteria:\n\n1. Anyone below 18 years of age.\n2. Patients on current anticoagulant and\u002For antiplatelet therapy\n3. Patients with a history of thrombotic events\n4. Patients with a coagulation disorder.\n5. Patients with recognized thrombophilia.\n6. Patients who cannot understand\u002Fspeak or read in English.",{"count":671,"type":20},50,[159],"This clinical trial will investigate the ability of thromboelastrogrpahy (TEG®) to detect hypercoagulability after liver surgery and will examine the effect of extended thromboprophylaxis (medical treatment to prevent the development of blood clots inside blood vessels) in patients undergoing liver surgery for cancer treatment.\n\nThe liver plays a key role in regulating the process of blood clotting. As a result, blood clots are a major cause of complications and death following liver surgery. This is especially true in cancer patients who are at a higher risk of developing blood clots. Current methods for preventing clotting complications after liver surgery include conventional coagulation blood tests (CCTs) and anticoagulant drugs, such as low molecular weight heparins (LMWHs). Current LMWH treatment is prescribed for one month after surgery, but studies show that the risk of developing blood clots can last up to 3 months. Studies also show that CCTs may not be as effective in detecting clotting issues as more comprehensive testing systems, such as TEG. This study will randomize 50 participants to receive 90 days of thromboprophylaxis (using the LMWH Redesca) or the standard of care 30 days (using the LMWH Fragmin) after liver surgery. The medication will be given by injection, similar to a regular vaccine or an insulin injection. Participants will inject the medication every day, for 30 or 90 days, after surgery. Participants will also have their blood tested for clotting issues via TEG testing before surgery and on post-operative days 1,3,5,30 and 90. After surgery, participants will be monitored by their surgeon for clotting complications and 3 year disease-free survival.",[675,139,676,677],"Hepatic Disease","Hypercoagulability","Thrombosis","2024-04-22",{"date":680,"type":38},"2024-04-23",{"date":682,"type":20},"2024-06-01",{"date":684,"type":20},"2028-02-01",{"name":686,"class":45},"Western University, Canada"]